U.S. officials have approved another Alzheimer's drug, Eli Lilly's Kisunla, for mild or early cases, offering delay in cognitive decline by about seven months, with potential downsides of IV infusions and brain swelling.
Physicians view Kisunla approval as crucial progress after failed treatments, providing hope for patients and families affected by Alzheimer's disease.
Collection
[
|
...
]